AR117715A1 - Interferón hiperglicosilado con inmunogenicidad reducida - Google Patents

Interferón hiperglicosilado con inmunogenicidad reducida

Info

Publication number
AR117715A1
AR117715A1 ARP190103715A ARP190103715A AR117715A1 AR 117715 A1 AR117715 A1 AR 117715A1 AR P190103715 A ARP190103715 A AR P190103715A AR P190103715 A ARP190103715 A AR P190103715A AR 117715 A1 AR117715 A1 AR 117715A1
Authority
AR
Argentina
Prior art keywords
interferon
reduced immunogenicity
hyperglycosylated
nucleic acid
acid molecule
Prior art date
Application number
ARP190103715A
Other languages
English (en)
Inventor
William D Martin
Groot Anne Searls De
Marina Etcheverrigaray
Sofa Ins Giorgetti
Eduardo Federico Mufarrege
Original Assignee
Univ Nacional Del Litoral Unl
Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Epivax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nacional Del Litoral Unl, Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet, Epivax Inc filed Critical Univ Nacional Del Litoral Unl
Priority to ARP190103715A priority Critical patent/AR117715A1/es
Priority to BR112022011975A priority patent/BR112022011975A2/pt
Priority to JP2022537837A priority patent/JP2023514659A/ja
Priority to EP20901063.6A priority patent/EP4076504A4/en
Priority to US17/783,948 priority patent/US20230127506A1/en
Priority to PCT/US2020/065246 priority patent/WO2021126929A1/en
Priority to MX2022007546A priority patent/MX2022007546A/es
Publication of AR117715A1 publication Critical patent/AR117715A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente describe un interferón hiperglicosilado con inmunogenicidad reducida y mayor estabilidad. Además, se describe una molécula de ácido nucleico que codifica para dicho interferón; una célula de expresión de proteínas recombinantes que comprende dicha molécula de ácido nucleico que codifica para dicho interferón modificado; donde dicha célula de expresión de proteínas recombinantes comprende un plásmido o vector que contiene dicha molécula de ácido nucleico. También se describe una formulación farmacéutica que comprende el interferón hiperglicosilado con inmunogenicidad reducida. Reivindicación 1: Un interferón hiperglicosilado con inmunogenicidad reducida caracterizado porque comprende la sustitución de al menos 5 aminoácidos de alguna de las posiciones seleccionadas del conjunto comprendido por: 23, 31, 61, 79, 80, 131, 142, 137, 161 y 171; donde dicha sustitución comprende el cambio del aminoácido de dicha posición por alanina o glicina. Reivindicación 23: El uso del interferón de las reivindicaciones 1 - 9 para el tratamiento de enfermedades seleccionadas del conjunto comprendido por: hepatitis B crónica, hepatitis C crónica.
ARP190103715A 2019-12-17 2019-12-17 Interferón hiperglicosilado con inmunogenicidad reducida AR117715A1 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ARP190103715A AR117715A1 (es) 2019-12-17 2019-12-17 Interferón hiperglicosilado con inmunogenicidad reducida
BR112022011975A BR112022011975A2 (pt) 2019-12-17 2020-12-16 Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo
JP2022537837A JP2023514659A (ja) 2019-12-17 2020-12-16 免疫原性が低下した修飾インターフェロン－アルファ－２
EP20901063.6A EP4076504A4 (en) 2019-12-17 2020-12-16 MODIFIED INTERFERON ALPHA-2 WITH REDUCED IMMUNOGENICITY
US17/783,948 US20230127506A1 (en) 2019-12-17 2020-12-16 Modified interferon-alpha-2 having reduced immunogenicity
PCT/US2020/065246 WO2021126929A1 (en) 2019-12-17 2020-12-16 Modified interferon-alpha-2 having reduced immunogenicity
MX2022007546A MX2022007546A (es) 2019-12-17 2020-12-16 Interferon-alfa-2 modificado que tiene inmunogenicidad reducida.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP190103715A AR117715A1 (es) 2019-12-17 2019-12-17 Interferón hiperglicosilado con inmunogenicidad reducida

Publications (1)

Publication Number Publication Date
AR117715A1 true AR117715A1 (es) 2021-08-25

Family

ID=76478524

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103715A AR117715A1 (es) 2019-12-17 2019-12-17 Interferón hiperglicosilado con inmunogenicidad reducida

Country Status (7)

Country Link
US (1) US20230127506A1 (es)
EP (1) EP4076504A4 (es)
JP (1) JP2023514659A (es)
AR (1) AR117715A1 (es)
BR (1) BR112022011975A2 (es)
MX (1) MX2022007546A (es)
WO (1) WO2021126929A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024040247A1 (en) 2022-08-18 2024-02-22 Regeneron Pharmaceuticals, Inc. Interferon proproteins and uses thereof
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
CN116814595B (zh) * 2023-08-30 2023-11-28 江苏申基生物科技有限公司 一种腺苷脱氨酶突变体及其固定化

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0207704A (pt) * 2001-03-02 2004-07-06 Merck Patent Ges Mit Beschaenk Alfa interferon modificado com imunogenicidade reduzida
CA2576030A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
ATE529442T1 (de) * 2005-06-03 2011-11-15 Ambrx Inc Verbesserte humane interferon-moleküle und ihre verwendungen
CA2613737C (en) * 2005-06-29 2017-05-23 Yeda Research And Development Co. Ltd. Recombinant interferon .alpha.2 (ifn.alpha.2) mutants
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CA2965414C (en) * 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
AR102120A1 (es) * 2015-09-29 2017-02-08 Univ Nac Del Litoral Interferón modificado con inmunogenicidad reducida
CN112105632A (zh) * 2018-01-24 2020-12-18 北京智康博药肿瘤医学研究有限公司 细胞因子融合蛋白

Also Published As

Publication number Publication date
EP4076504A4 (en) 2024-04-10
BR112022011975A2 (pt) 2022-08-30
MX2022007546A (es) 2022-11-30
US20230127506A1 (en) 2023-04-27
JP2023514659A (ja) 2023-04-07
WO2021126929A1 (en) 2021-06-24
EP4076504A1 (en) 2022-10-26

Similar Documents

Publication Publication Date Title
AR117715A1 (es) Interferón hiperglicosilado con inmunogenicidad reducida
EA201892671A1 (ru) Пегилированный свиной интерферон и способы его применения
JP2023179436A5 (es)
HRP20231496T1 (hr) Cistein proteaza
WO2018067217A3 (en) COMPOSITIONS COMPRISING SHORT PEPTIDES DERIVED FROM PEDF AND USES THEREOF
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
BR112018073909A2 (pt) proteínas klotho recombinantes terapêuticas e composições e métodos envolvendo as mesmas
PE20211469A1 (es) Proteinas f de prefusion del vrs estabilizadas
SI3079715T1 (en) A mixture of peptides
CY1114030T1 (el) Ομοιογενη παρασκευασματα toy il-29
AR087227A1 (es) CONJUGADO DE INTERFERON a CON POLIETILENGLICOL
AR058567A1 (es) Formulaciones de proteinas estables
CL2019003409A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
BR112022009670A2 (pt) Polipeptídeos efetores de crispr-cas e métodos de uso dos mesmos
BR112021023957A2 (pt) Peptídeos
MX2021013743A (es) Subunidad s1 modificada de la proteina de espicula de coronavirus.
CA2692358A1 (en) Recombinant human interferon-like proteins
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
CO2023000048A2 (es) Conjugados de citoquina
AR035077A1 (es) Polipeptidos de neublastina variante, proteinas de fusion, acidos nucleicos, vectores, celulas hospedadoras, metodos para producir dichos polipeptidos, dimeros, conjugados, composiciones farmaceuticas y uso de dichos polipeptidos en la preparacion de medicamentos
CL2021003474A1 (es) Producto farmacéutico para terapia enzimática para tratamiento de homocistinuria
RU2016135003A (ru) Новые виды лечения
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
AR123187A1 (es) Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer
AR027484A1 (es) Proteina de fusion util en el tratamiento o prevencion del herpes zoster y en la prevencion o tratamiento de infecciones de varicela, adn y arn quecodifican dicha proteina; vectores de expresion y microorganismos recombinantes que comprenden dicho adn o arn; composiciones de vacuna que incluyen dich